[go: up one dir, main page]

NO180381C - DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær - Google Patents

DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær

Info

Publication number
NO180381C
NO180381C NO883346A NO883346A NO180381C NO 180381 C NO180381 C NO 180381C NO 883346 A NO883346 A NO 883346A NO 883346 A NO883346 A NO 883346A NO 180381 C NO180381 C NO 180381C
Authority
NO
Norway
Prior art keywords
yeast
heterologous
factor leader
secretion
leader sequence
Prior art date
Application number
NO883346A
Other languages
English (en)
Other versions
NO180381B (no
NO883346L (no
NO883346D0 (no
Inventor
Anthony J Brake
Johannes A Van Den Berg
Original Assignee
Gist Brocades Nv
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gist Brocades Nv, Chiron Corp filed Critical Gist Brocades Nv
Publication of NO883346D0 publication Critical patent/NO883346D0/no
Publication of NO883346L publication Critical patent/NO883346L/no
Publication of NO180381B publication Critical patent/NO180381B/no
Publication of NO180381C publication Critical patent/NO180381C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NO883346A 1987-07-28 1988-07-28 DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær NO180381C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/078,551 US5010182A (en) 1987-07-28 1987-07-28 DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides

Publications (4)

Publication Number Publication Date
NO883346D0 NO883346D0 (no) 1988-07-28
NO883346L NO883346L (no) 1989-01-30
NO180381B NO180381B (no) 1996-12-30
NO180381C true NO180381C (no) 1997-04-09

Family

ID=22144759

Family Applications (1)

Application Number Title Priority Date Filing Date
NO883346A NO180381C (no) 1987-07-28 1988-07-28 DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær

Country Status (19)

Country Link
US (1) US5010182A (no)
EP (1) EP0301669B1 (no)
JP (1) JP2680054B2 (no)
KR (1) KR970004940B1 (no)
CN (1) CN1045620C (no)
AT (1) ATE90727T1 (no)
AU (1) AU623860B2 (no)
CA (1) CA1327762C (no)
DE (1) DE3881776T2 (no)
DK (1) DK175365B1 (no)
ES (1) ES2058238T3 (no)
FI (1) FI101232B1 (no)
HU (1) HU213015B (no)
IE (1) IE62261B1 (no)
IL (1) IL87255A (no)
NO (1) NO180381C (no)
NZ (1) NZ225596A (no)
PT (1) PT88115B (no)
ZA (1) ZA885535B (no)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0763543A2 (en) 1988-09-02 1997-03-19 The Rockefeller University A method for preparing an inflammatory cytokine (MIP-2) and diagnostic and therapeutic applications for the cytokine or its antibody
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
AU5013893A (en) * 1992-08-14 1994-03-15 Rockefeller University, The Herpesviral defective vector with rat preproenkephalin gene promoter
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
WO1999021998A1 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
JP2001523977A (ja) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
CA2293740A1 (en) 1997-06-18 1998-12-23 Genentech, Inc. Apo-2dcr, a tnf-related receptor
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
ES2331900T3 (es) * 1997-08-26 2010-01-19 Genentech, Inc. Receptor rtd.
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
PT1015587E (pt) * 1997-09-18 2008-07-31 Genentech Inc Polipéptido dcr3, um homólogo de tnfr
EP1967587A1 (en) 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316182T3 (es) 1998-01-15 2009-04-01 Genentech, Inc. Ligando apo-2.
US6727079B1 (en) * 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
IL138488A0 (en) 1998-03-17 2001-10-31 Genentech Inc Polypeptides homologous to vegf and bmp1
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CA2328496C (en) 1998-05-15 2016-01-05 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
IL139419A0 (en) * 1998-06-12 2001-11-25 Genentech Inc Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
CA2354027A1 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
AU1095001A (en) 1999-10-20 2001-04-30 Genentech Inc. Type i cytokine receptor tccr
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
WO2001049859A1 (en) 1999-12-30 2001-07-12 Genencor International, Inc. Trichoderma reesei xylanase
CN1425066B (zh) * 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
ES2275675T3 (es) 2000-03-23 2007-06-16 Elan Pharmaceuticals, Inc. Compuestos y metodos para tratar la enfermedad de alzheimer.
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
DK1266018T3 (da) * 2000-03-24 2008-09-01 Genencor Int Fremstilling af udskilte proteiner af rekombinante, eukaryotiske celler
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ES2252257T3 (es) * 2000-06-30 2006-05-16 Elan Pharmaceuticals, Inc. Compuestos para tratar la enfermedad de alzheimer.
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100628425B1 (ko) 2001-06-20 2006-09-28 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
WO2003020892A2 (en) * 2001-08-29 2003-03-13 Genentech, Inc. Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US7705195B2 (en) * 2002-06-07 2010-04-27 Genentech, Inc. Screening method
EP2383278A1 (en) 2002-07-08 2011-11-02 Genentech, Inc. Method to determine B cell mediated diseases
EP1578373A4 (en) 2002-09-11 2007-10-24 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2498274A1 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2364716A3 (en) 2002-11-08 2012-01-11 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7118901B2 (en) 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
AU2004259638C1 (en) 2003-07-08 2018-12-20 Novartis Pharma Ag IL-17 A/F heterologous polypeptides and therapeutic uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
ATE453405T1 (de) 2003-11-17 2010-01-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
DE602004031881D1 (de) * 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) * 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
BRPI0617688A2 (pt) 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
LT2656841T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
CA2662610A1 (en) * 2006-10-24 2008-05-02 Novozymes A/S Improved alpha factor signal peptide for producing a polypeptide
US20080254512A1 (en) 2006-11-02 2008-10-16 Capon Daniel J Hybrid immunoglobulins with moving parts
NZ578980A (en) 2007-02-22 2012-03-30 Genentech Inc Methods for detecting inflammatory bowel disease
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
EP2641618A3 (en) 2007-07-16 2013-10-23 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
SI2592148T1 (sl) 2007-10-12 2018-12-31 F. Hoffmann-La Roche Ag Izražanje beljakovin iz več nukleinskih kislin
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
CN104650230A (zh) 2008-01-31 2015-05-27 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EP2414399A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2258855A1 (en) 2009-05-28 2010-12-08 Universität für Bodenkultur Wien Expression sequences
RU2573896C2 (ru) * 2009-10-15 2016-01-27 Дженентек, Инк. Химерные факторы роста фибробластов с измененной рецепторной специфичностью
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
RU2015132142A (ru) 2009-11-30 2015-12-20 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
MA34291B1 (fr) 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
BR112012033121B1 (pt) 2010-06-25 2019-08-20 Institut Pasteur De Lille Métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103797026A (zh) 2010-09-15 2014-05-14 阿利吉那科技有限公司 由木质素衍生的化合物生物生产芳香族化学品
RU2627597C2 (ru) 2011-11-23 2017-08-09 Ф. Хоффманн-Ля Рош Аг Клетки млекопитающих, экспрессирующие лиганд cd40l, и их применение
EP2839011B1 (en) 2012-04-17 2016-09-14 F. Hoffmann-La Roche AG Method for the expression of polypeptides using modified nucleic acids
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
US10160988B2 (en) 2012-10-29 2018-12-25 Lonza Ltd Expression sequences
US20160186221A1 (en) 2012-12-07 2016-06-30 Danisco Us Inc. Compositions and methods of use
CA2892054A1 (en) 2012-12-07 2014-06-12 Ling Hua Compositions and methods of use
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
US20170211053A1 (en) 2014-09-30 2017-07-27 Danisco Us Inc. Compositions comprising beta mannanase and methods of use
WO2016054194A1 (en) 2014-09-30 2016-04-07 1/1Danisco Us Inc Compositions comprising beta-mannanase and methods of use
US20170226494A1 (en) 2014-09-30 2017-08-10 Danisco Us Inc. Compositions comprising beta-mannanase and methods of use
WO2016054205A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
US20170218351A1 (en) 2014-09-30 2017-08-03 Danisco Us Inc. Compositions comprising beta-mannanase and methods of use
US20180002683A1 (en) 2014-12-18 2018-01-04 Danisco Us Inc. Engineered multifunctional enzymes and methods of use
US20170362621A1 (en) 2014-12-18 2017-12-21 Danisco Us Inc. Engineered multifunctional enzymes and methods of use
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
PL3436571T3 (pl) 2016-03-30 2023-09-25 F. Hoffmann-La Roche Ag Sposób hodowli limfocytów B
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
JP6916884B2 (ja) 2017-01-02 2021-08-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ細胞培養法
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
EP3625332B1 (en) 2017-05-19 2022-02-02 F. Hoffmann-La Roche AG Method for the production of thymocyte supernatant
CN109022478A (zh) * 2017-06-09 2018-12-18 康码（上海）生物科技有限公司 一种用于高通量体外蛋白质合成的dna元件
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
ES2932861T3 (es) 2018-01-26 2023-01-27 Hoffmann La Roche Composiciones de IL-22 Fc y procedimientos de uso
MA51676A (fr) 2018-01-26 2021-05-05 Hoffmann La Roche Protéines de fusion il-22 fc et procédés d'utilisation
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
JP7511591B2 (ja) 2019-06-28 2024-07-05 エフ． ホフマン－ラ ロシュ アーゲー 抗体の製造方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2024044550A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0116201B1 (en) * 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
AU2722184A (en) * 1983-04-25 1984-11-01 Genentech Inc. Use of alpha sequences in yeast expression systems
JPS6156078A (ja) * 1984-07-27 1986-03-20 Suntory Ltd 酵母を宿主とする分泌発現ベクタ−
HU208553B (en) * 1987-07-28 1993-11-29 Gist Brocades Nv Process for producing polypeptides, plasmides coding them and transformed kluyveromyces
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences

Also Published As

Publication number Publication date
NZ225596A (en) 1991-04-26
PT88115A (pt) 1989-06-30
NO180381B (no) 1996-12-30
IE62261B1 (en) 1995-01-11
HUT47638A (en) 1989-03-28
FI101232B (fi) 1998-05-15
DK422288D0 (da) 1988-07-28
DE3881776T2 (de) 1993-11-18
NO883346L (no) 1989-01-30
CA1327762C (en) 1994-03-15
EP0301669B1 (en) 1993-06-16
PT88115B (pt) 1995-03-01
AU623860B2 (en) 1992-05-28
AU2013688A (en) 1989-02-02
FI101232B1 (fi) 1998-05-15
CN1045620C (zh) 1999-10-13
DK175365B1 (da) 2004-09-13
DE3881776D1 (de) 1993-07-22
HU213015B (en) 1997-01-28
FI883541A0 (fi) 1988-07-28
ES2058238T3 (es) 1994-11-01
US5010182A (en) 1991-04-23
NO883346D0 (no) 1988-07-28
JP2680054B2 (ja) 1997-11-19
EP0301669A1 (en) 1989-02-01
KR970004940B1 (ko) 1997-04-10
ATE90727T1 (de) 1993-07-15
IL87255A0 (en) 1988-12-30
FI883541L (fi) 1989-01-29
CN1032367A (zh) 1989-04-12
KR890002406A (ko) 1989-04-10
JPH01124390A (ja) 1989-05-17
DK422288A (da) 1989-01-29
ZA885535B (en) 1989-04-26
IL87255A (en) 1993-04-04
IE882313L (en) 1989-01-28

Similar Documents

Publication Publication Date Title
NO180381C (no) DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær
ATE265538T1 (de) Verfahren zur sekretion thrombopoitin polypeptide
AP8600035A0 (en) Hepatitis B surface antigen formed by recombinant DNA Techniques, vaccines, diagnostics, cell lines and methods of forming same.
FI901428A0 (fi) Peptid och dna-sekvenser.
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
DE69534822D1 (de) Verfahren zur bakteriellen herstellung von heterologen polypeptiden mit disulfidbrücke
DK111183A (da) Polypeptid omfattende aminosyresekvensen af et dyreinterferon, dna-sekvens, der koder for polypeptidet, replicerbart udtrykkelsesmedium, som kan udtrykke dna-sekvensen, og fremgangsmaade til fremstilling af polypeptidet
DK595286A (da) Fremgangsmaade til fremstilling af thrombininhibitorer
ATA192895A (de) Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
ATE95242T1 (de) Hefe-expressionssystem.
KR840008697A (ko) 상동 효모 신호를 이용한 이종단백질의 합성, 분비 및 표현매개체 제조방법
SE8800378D0 (sv) Production of fused proteins or polypeptides
KR870007280A (ko) 바실러스에서의 사람 혈청 알부민의 제조방법
GB2229184B (en) A gene coding for glucuronide permease
SE8802939D0 (sv) A method for the production and isolation of a fusion protein in eukaryotic cells
FI861559L (fi) Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut
ATE154392T1 (de) Kalzium-geregelter promotor

Legal Events

Date Code Title Description
MK1K Patent expired